AVIR
Atea Pharmaceuticals Inc
NASDAQ: AVIR · HEALTHCARE · BIOTECHNOLOGY
$5.51
+1.47% today
Updated 2026-04-30
Market cap
$435.81M
P/E ratio
—
P/S ratio
1.55x
EPS (TTM)
$-1.94
Dividend yield
—
52W range
$2 – $6
Volume
0.5M
WallStSmart proprietary scores
54
out of 100
Grade: C
Hold
Investment rating
8.3
Growth
A8.5
Quality
A3.0
Profitability
D6.7
Valuation
B2/9
Piotroski F-Score
Weak
9.0
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$8.83
+60.25%
12-Month target
—
—
Intrinsic (DCF)
$10.35
Margin of safety
+56.91%
0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 8.97 — safe zone
+ Revenue growth 295.20% QoQ
+ 56.91% below intrinsic value
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-28.22M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $192.18M | $0.00 | $0.00 | $0.00 | $192.18M |
| Net income | $-115.91M | $-135.96M | $-168.38M | $-158.35M | $-44.87M |
| EPS | — | — | — | — | $-1.94 |
| Free cash flow | $-122.92M | $-85.39M | $-135.50M | $-132.03M | $-28.22M |
| Profit margin | -60.31% | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-11 | CORCORAN, ANDREA | Buy | 60,000 | — |
| 2026-03-11 | CORCORAN, ANDREA | Buy | 60,000 | $1.24 |
| 2026-02-03 | SOMMADOSSI, JEAN-PIERRE | Sale | 300,000 | — |
Peer comparison
Smart narrative
Atea Pharmaceuticals Inc trades at $5.51. Our Smart Value Score of 54/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 8.97, it sits in the safe zone. TTM revenue stands at $192.18M. Our DCF model estimates intrinsic value at $10.35.
Frequently asked questions
What is Atea Pharmaceuticals Inc's stock price?
Atea Pharmaceuticals Inc (AVIR) trades at $5.51.
Is Atea Pharmaceuticals Inc overvalued?
Smart Value Score 54/100 (Grade C, Hold). DCF value $10.35.
What is the price target of Atea Pharmaceuticals Inc (AVIR)?
The analyst target price is $8.83, representing +60.3% upside from the current price of $5.51.
What is the intrinsic value of Atea Pharmaceuticals Inc (AVIR)?
Based on our DCF model, intrinsic value is $10.35, a +56.9% margin of safety versus $5.51.
What is Atea Pharmaceuticals Inc's revenue?
TTM revenue is $192.18M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
8.97 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.55x
ROE-44.30%
Beta0.16
50D MA$5.42
200D MA$3.89
Shares out0.08B
Float0.06B
Short ratio—
Avg volume0.5M
Performance
1 week-4.46%
1 month+5.51%
3 months+38.50%
YTD+50.14%
1 year—
3 years—
5 years—